Assessment of Zinc Alpha-2 Glycoprotein Level in Gestational Diabetes Woman in Respect to Glycemic Status with and without Treatment
Background: Gestational diabetes is a pathological condition that manifests between the 2nd and 3rd trimesters of pregnancy. It is distinguished by substantial insulin resistance induced by the secretion of placental hormone. Adipocytes secrete a particular type of adipocytokine called zinc a2 glyc...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
College of Pharmacy / Mustansiriyah University
2025-01-01
|
| Series: | Al-Mustansiriyah Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/1127 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Gestational diabetes is a pathological condition that manifests between the 2nd and 3rd trimesters of pregnancy. It is distinguished by substantial insulin resistance induced by the secretion of placental hormone. Adipocytes secrete a particular type of adipocytokine called zinc a2 glycoprotein (ZAG), and numerous reasearches have suggested that ZAG is involved in crucial physiological processes such as glucose metabolism.
Objectives: This study was designed to evaluate the ZAG level in GDM pregnant women on different therapeutic modalities and whether it could be used as a biomarker in the diagnosis of GDM. Also to study the correlation between ZAG with glycemic status. Method: The research included 76 pregnant women (age 18–40), 22 healthy pregnant women (group1), 30 newly diagnosed GDM pregnant women (group2), and 24 GDM on different therapeutic modalities (group3), in the 2nd or 3rd trimester; all the demographic and glycemic characteristics were measured.
Result: There was no substantial difference in ZAG levels of the study groups from one another (P≥ 0.05); therefore, pregnant women with GDM in group 2 exhibited the greatest level of ZAG. Significant variation in ZAG levels was observed among subgroups of treated GDM pregnant women (p<0.01). The metformin group exhibited the lowest level of ZAG. There was significant increase in Fasting Blood Glucose and Glycated Hemoglobin in GDM pregnant women group 2 and 3 compared to group 1 pregnant women, meanwhile, slight increase in fasting plasma insulin level and Homeostatic Model Assessment of Insulin Resistance (HOMA IR) among group 2 and 3 compared to group 1 pregnant women, though not noticeable (P≥ 0.05). No statistically significant association was reported with ZAG and glycemic indices.
Conclusion: there was no statistically significant variation in ZAG level within study groups (P≥ 0.05), hence, GDM pregnant women in group 2 showed the highest level. ZAG could not be used as an indicator in the diagnosis of GDM.
|
|---|---|
| ISSN: | 1815-0993 2959-183X |